Synairgen (LON:SNG)‘s stock had its “corporate” rating reaffirmed by analysts at FinnCap in a research report issued on Wednesday.
SNG opened at GBX 17 ($0.22) on Wednesday. Synairgen has a 1 year low of GBX 6.88 ($0.09) and a 1 year high of GBX 32 ($0.42).
Synairgen Company Profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Read More: Trading Strategy
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.